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In this issue of Cardiology Journal, Alizadeh et al.
[1] report their findings prospectively comparing
the risk of thrombosis following one vs multiple
venous puncture sites for the placement of sheaths
used to perform electrophysiology (EP) studies.
The authors also assessed the effects of heparin on
the incidence of thrombosis. In situ thrombosis was
defined as the presence of: “a strand of thrombus
connected to the tip of the catheter at the time of
removal.” Duplex ultrasonography was obtained
24 h after the EP study to screen for the formation
of deep venous thrombosis (DVT).
The first notable finding was that subjects with
multiple sheaths placed via a single venous punc-
ture site were at greater risk of in situ thrombosis
than those with multiple puncture sites (38% vs
18%). Importantly, a statistically significant reduc-
tion in the incidence of in situ thrombosis was ob-
served in the single venous puncture group treated
with heparin (16% vs 38%; p = 0.023), something
that was not observed in the other group. The se-
cond notable finding was that no DVTs were iden-
tified in this study.
Percutaneous catheterization using the
Seldinger technique was originally described by
Sven Ivar Seldinger [2]. Adaptations of the
guidewire method led to the development of venous
catheterization that revolutionized the delivery of
cardiovascular medicine. Moncrief provided one of
the earliest reports of the consequences of femoral
venous catheterization [3]. This report included
135 instances of femoral venous access in 91 patients.
In this study, DVT was the most frequent compli-
cation, occurring in 13.3% of cases. The duration
of catheter placement correlated directly with ad-
verse events. The long-term sequelae of DVTs and
deaths due to thrombophlebitis led Moncrief to con-
clude: “Femoral catheters should be utilized only
when all other methods of intravenous infusion have
been exhausted, and when in use should remain in
a single femoral location for not more than seven
to ten days.”
Despite recent advances, vascular complica-
tions, such as hematomas, atrio-ventricular fistu-
lae and DVTs are not uncommon following femoral
venous catheterization for electrophysiology stu-
dies. Virchow’s triad is a common eponym used to
describe three components essential to intravascu-
lar thrombosis: inflammation of the vessel wall, sta-
sis of blood flow, and a hypercoaguable state. Thus,
placement of venous sheaths promotes vascular
thrombosis by contributing to venous stasis and
inciting vascular inflammation.
Studies in critically ill and trauma patients re-
port an incidence of 9.6–26% for ileofemoral DVT
formation (detected by ultrasonography) following
femoral vein cannulation for central venous access,
but do not comment on the incidence of thromboem-
bolic complications [4–7]. Neither Joynt et al. [4]
nor Mian et al. [6] found an association between age,
gender, number of insertion attempts, length of
catheter duration, or use of DVT prophylaxis and
the risk of DVT formation.
Unlike critically ill populations, patients under-
going EP studies tend to be healthier and are ex-
posed to shorter durations of indwelling catheters.
Despite these differences, the incidence of asymp-
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tomatic DVT formation remains high, ranging 16–
–44% for ileofemoral DVT formation by ultrasono-
graphy following sheath placement for EP studies [8–
–10]. However, the incidence of symptomatic DVTs
is much lower (0.5–0.8%). The risk of thromboem-
bolic complications following EP procedures also re-
mains low, ranging 0.8–1.3% [11–14]. Importantly,
not all thromboembolic complications result from
DVT formation. Ablation itself and left-sided pro-
cedures are independently associated with throm-
boembolic complications. Results from the Multi-
center European Radiofrequency Survey (MERFS)
provided the largest cohort of 4,398 patients re-
ferred for catheter ablation of supraventricular or
ventricular tachycardias [14]. DVTs were identified
in 0.5% of patients, while thromboembolic compli-
cations occurred in 0.8% of patients. The risk of
embolic events following right-sided procedures
was extraordinarily uncommon (0.06%) in MERFS.
Importantly, this study did not provide information
regarding periprocedural use of anticoagulation.
As noted above, several studies have reported
a relatively frequent incidence of asymptomatic
DVTs following EP studies. Chen et al. [8] report-
ed an incidence of 17.6% for the development of
asymptomatic, non-occlusive DVTs identified by
duplex ultrasonography one day following invasive
EP studies using multiple venous sheaths. Repeat
ultrasonography at one week documented regres-
sion of the non-occlusive DVTs in 92% of cases.
Embolic complications were extremely rare in this
study, occurring in 0.14% of patients following ra-
diofrequency ablation. Heparin, 5,000 U bolus fol-
lowed by 1,000 U/h, was administered in all patients
who underwent left-sided procedures.
A similar incidence of asymptomatic thrombo-
sis (20%; n = 24) by ultrasonography was reported
by Tiroke et al. [9] despite the use of intravenous
heparin, which was titrated to a target ACT > 200 s.
The risk of thrombosis was independent of age,
gender, duration of study or number of sheaths.
Importantly, six hours of banding were used to
maintain hemostasis following sheath removal. The
role of different methods used to obtain hemosta-
sis following sheath removal (i.e. banding vs 15–
–20 min of firm pressure) has not yet been ade-
quately studied.
The importance of intravenous heparin to mini-
mize thromboembolic complications during left-
-sided procedures, specifically catheter ablation of
atrial fibrillation, is well-established [15, 16]. How-
ever, its utility during right-sided EP studies re-
mains unclear. Green et al. [11] reported an inci-
dence of 0.8% for DVT formation in subjects who
underwent radiofrequency ablation for supraven-
tricular arrhythmias despite heparin initiated with
a 5,000 U bolus followed by 1,000 U/h infusion
throughout the procedure. The article by Alizadeh
et al. [1] found a reduction in in situ thrombosis
when using a single vs multiple venous puncture
sites, but no significant differences when multiple
puncture sites were used.
Low molecular weight heparin has also been
shown to reduce the risk of catheter-related throm-
bosis. A study by Davutoglu et al. [10] reported
a significantly lower incidence of venous thrombo-
sis (18.2%; n = 2 vs 62.5%; n = 10; p = 0.02), as-
sessed by ultrasound, in subjects who received
a single 5,000 U injection of Dalteparin one hour pri-
or to multiple venous sheath placement for EP
study. All subjects, except one, demonstrated com-
plete resolution following one month of anticoagu-
lation with warfarin.
The study by Alizadeh et al. [1] adds to our
understanding of the risk of thrombotic complica-
tions during EP study. First, this study suggests
that the approach to femoral cannulation matters,
with a reduced incidence of in situ thrombosis as-
sociated with multiple venous punctures compared
to single puncture site. Female gender and proce-
dure time increased the risk of in situ thrombosis,
which should be taken into consideration. Meticu-
lous sheath management with frequent flushing, or
perhaps continuous irrigation, should be considered
in such cases. It is surprising that no DVTs were
identified in this study. This may reflect a limita-
tion of the sample size, or perhaps other factors
such as sheath management or methods used to
achieve hemostasis following sheath pull.
In addition to the limitations of the study out-
lined by the authors, the presence of in situ throm-
bosis, as defined in this study, is of unclear and like-
ly minor clinical significance. Importantly, it was not
associated with DVT formation, since no subjects
in the study developed DVTs.
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